- Marvel Biosciences (MRVL) has completed a manufacturing milestone required to begin Phase 1 human trials targeting Alzheimer’s disease and depression
- The company successfully completed a multi-kilogram scale run under current good manufacturing practices (cGMP) of the active pharmaceutical ingredient (API) of the company’s lead asset MB-204
- Marvel Biosciences Corp. is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development
- Marvel Biosciences Corp. was unchanged at $0.125 at 12:49 PM ET
Marvel Biosciences (MRVL) has completed a manufacturing milestone required to begin Phase 1 human trials targeting Alzheimer’s disease and depression.
Marvel Biosciences Corp., with its wholly-owned subsidiary, Marvel Biotechnology Inc. successfully completed a multi-kilogram scale run under current good manufacturing practices (cGMP) of the active pharmaceutical ingredient (API) of the company’s lead asset MB-204.
Marvel completed the milestone in partnership with Zhejiang Ausun Pharmaceutical Co., Ltd.
The cGMP material obtained from this study will be utilized in the company’s upcoming Phase 1 clinical study.
“We are pleased to have achieved yet another manufacturing milestone in producing clinical grade MB-204 API with our manufacturing partner Ausun,” stated Rod Matheson, Chief Executive Officer of Marvel Biosciences.
“We are planning our Phase 1 human trials and we look forward to updating the market with news on our 4-week GLP toxicology studies shortly,” he added.
In the United States, it is estimated that one in 10 senior citizens over the age of 65 suffer from dementia. MB-204 is a novel solution to Alzheimer’s that has similar properties to the FDA-approved drug Istradefylline.
MB-204 has, through the company’s studies, proven to be more effective and longer lasting, while offering a higher reduction in depression and anxiety symptoms.
Marvel Biosciences Corp., with its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a “drug redevelopment” approach to drug development.
Marvel Biosciences Corp. was unchanged at $0.125 at 12:49 PM ET.
